Ambit Biosciences Corporation

Kei Motonaga

Takumi Hara

Emiko Murayama

Shinsuke Oba

Hiroyasu Toyota

Satomi Ikeuchi

Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N&#x2032;-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-&#x3b2;-cyclodextrin in a ratio ranging from 1:8 to 1:20.

Growing community of inventors

Tokyo, Japan

Kei Motonaga